Comparative Pharmacology
Head-to-head clinical analysis: BETAXON versus ESMOLOL HYDROCHLORIDE DOUBLE STRENGTH IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BETAXON versus ESMOLOL HYDROCHLORIDE DOUBLE STRENGTH IN PLASTIC CONTAINER.
BETAXON vs ESMOLOL HYDROCHLORIDE DOUBLE STRENGTH IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selective beta-1 adrenergic receptor antagonist; reduces intraocular pressure by decreasing aqueous humor production through inhibition of beta-1 receptors in the ciliary epithelium.
Selective beta-1 adrenergic receptor antagonist with no intrinsic sympathomimetic activity or membrane stabilizing activity. Reduces heart rate, myocardial contractility, and blood pressure by blocking catecholamine effects at beta-1 receptors predominantly in cardiac tissue.
0.25% ophthalmic solution, 1 drop in the affected eye(s) twice daily.
Loading dose: 500 mcg/kg IV over 1 minute, followed by maintenance infusion of 50 mcg/kg/min IV for 4 minutes. Titrate by 50 mcg/kg/min increments every 4 minutes as needed to maximum of 200 mcg/kg/min. For double-strength (20 mg/mL) formulation, adjust infusion rate accordingly.
None Documented
None Documented
Terminal elimination half-life is 12-18 hours; prolonged in renal impairment (up to 36 hours).
Terminal elimination half-life is approximately 9 minutes. Clinical context: ultra-short acting beta-blocker, steady state achieved within 30 minutes.
Primarily renal (40-50% unchanged) and fecal (30-40% as metabolites); biliary excretion contributes minimally.
Rapid metabolism by red blood cell esterases; metabolites are inactive. Less than 2% excreted unchanged in urine.
Category C
Category A/B
Beta-Blocker
Beta-Blocker